Pharmacogenomic landscape of UGT1A1 in cancer patients from the Avera sequencing and analytics protocol (ASAP) registry

Analysis of UGT1A1 pharmacogenomic profiles in 564 cancer patients revealed that 53% had reduced metabolizer status, potentially increasing toxicity or reducing efficacy of UGT1A1-metabolized drugs. Among the 19 patients treated with irinotecan, 68% experienced grade 1-3 treatment-related adverse events (TRAEs), with 69% occurring in intermediate or poor metabolizers. These findings underscore the importance of preemptive UGT1A1 testing to help optimize irinotecan dosing and minimize toxicity.